Managed Markets Marketing—Psychiatry Team
Agency Partners: Warhaftig Associates and Xcenda
Sunovion Team Members:
Mark Weihmann, Director, Managed Markets Marketing—Psychiatry
Dan Bartolucci, Associate Director, Managed Markets Marketing—Psychiatry
Achieving Optimal Market Access Success
Within a crowded therapeutic landscape consisting mostly of generic atypical antipsychotic agents, the team behind Latuda had to differentiate and demonstrate value to achieve competitive formulary position that is viable for physician and patient access. And that remained true as Latuda continued to be approved for new indications since its initial launch in 2010 to treat schizophrenia in adults.
In the summer of 2013, Latuda was approved as monotherapy and adjunctive therapy for use in adult patients with bipolar depression. Then, in January of 2017, it was approved for use in adolescents for schizophrenia, and in March 2018 for use in pediatric patients (aged 10-17) for bipolar depression. Throughout this exciting evolution, the Latuda brand has seen incremental growth in payer access across commercial and government-sponsored channels. Mark Weihmann and Dan Bartolucci have been at the core of this managed markets success with their consistent vision and market access leadership through the life of the brand.
One of their signature achievements is the launch and recognition of the award-winning Sunovion Health Insights website: www.sunovionhealthinsights.com. The site was specifically designed for managed care decision-makers including medical directors, pharmacy directors, pharmacy and therapeutics (P&T) committee members, quality directors, case managers, accountable care organizations (ACOs), hospital/integrated delivery network (IDN) customers, and other population health team members. To serve these customers the site offers payers innovative solutions for population health management, new disease-state health facts, quality metrics, and much more.
Mark and Dan not only launched Sunovion Health Insights at its inception; they also helped expand it beyond their own brands to cover all of Sunovion’s portfolio, including neurology and respiratory health.
Exemplary of an incredible marketing team, Mark and Dan are dedicated to ensuring Latuda continues to be competitively positioned on health plan formularies, so that physicians and patients have access to all available therapeutic options in managing bipolar depression and schizophrenia, both complex psychiatric conditions.